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Pulmonary Langerhans cell histiocytosis (PLCH) is an uncommon diffuse lung disease characterized by
the abnormal accumulation of Langerhans' cells around small airways and other distal lung compart-
ments. Although pulmonary hypertension (PH) is a frequent complication of PLCH, the role of advanced
PH therapies for PLCH-related PH is not well-established. We describe a PLCH patient with severe,
disease-related PH that responded unexpectedly well to advanced PH therapy with sustained
improvement over a 10 year follow-up period. This case indicates that PLCH-associated PH may, in
certain instances, be highly responsive to advanced PH therapies and emphasizes the importance of
trialing these therapies among patients with PLCH-related PH.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Pulmonary Langerhans cell histiocytosis (PLCH) is an uncom-
mon smoking-related interstitial lung disease characterized by the
accumulation of specialized antigen presenting cells called Lang-
erhans' cells around small airways [1e3]. The natural history of this
disease is variable but often associated with life-threatening com-
plications such as pulmonary hypertension (PH). Although PLCH-
related PH is generally regarded as WHO (World Health Organi-
zation) group V PH disease for which the efﬁcacy of advanced PH
therapies is uncertain [4], a recent retrospective analysis showed
that a small cohort of PLCH patients treated with advanced PH
therapies had improved pulmonary vascular hemodynamics along
with a trend towards better survival [5]. We present a PLCH patient
with severe disease-related PH who achieved a dramatic and du-
rable therapeutic response with advanced PH therapies.Case report
A 46-year-old Caucasian woman presented in the fall of 2003
with complaints of progressive dyspnea (New York HeartCritical Care Medicine, Mayo
USA. Tel.: þ1 507 284 5398.
sallo).
Ltd. This is an open access article uAssociation: NHYA Class III) and non-productive cough. A diag-
nostic evaluation prior to her presentation at our facility resulted in
a surgical lung biopsy (December 2012) that established the diag-
nosis of Pulmonary Langerhans cell histiocytosis (PLCH). Other
pertinent medical history included an active 30 pack year smoking
history and mild and untreated obstructive sleep apnea (OSA).
Chest high resolution computed tomography revealed bilateral
cystic changes and scattered nodularity with an upper lung pre-
dominance and sparing of the costophrenic angles. Her surgical
lung biopsy slides from the outside facility were reviewed for
diagnostic conﬁrmation. Her lung specimens revealed multiple
nodules composed of Langerhans cells with mixed inﬂammatory
cells, cavitation and adjacent cystic changes (Fig. 1A). CD1a im-
munostaining identiﬁed the presence of increased Langerhans cells
(Fig. 1B). Pulmonary function testing demonstrated mild-moderate
expiratory air-ﬂow obstruction, preserved lung volumes, and
moderately reduced gas-exchange capacity. The index echocar-
diogram revealed normal ventricular structure and function with
an elevated right ventricular systolic pressure (RVSP) of 48 mmHg.
The patient was initially treated with prednisone (0.5 mg/kg/
day) without response, and then three cycles of 2-Chlorodeox-
yadenosine (5 mg/m2). The following year her symptoms and
pulmonary function remained stable, but a repeat echocardiogram
revealed an increase in RVSP to 63 mmHg. The patient underwentnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. A, Surgical lung biopsy demonstrating increased presence of inﬂammatory cells along with cavitary and cystic changes. B, Lung Biopsy with CD1a immunostaining
demonstrating the presence of increased Langerhans cells.
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pulmonary artery (mPA) pressure of 44 mmHg, pulmonary artery
wedge pressure of 12 mm Hg, cardiac output of 5.8 L/min, cardiac
index of 3.5 L/min/m2, and a pulmonary vascular resistance of 5.5
Wood units. Intravenous epoprostenol elicited a decrease in mPA to
38 mm Hg with pulmonary vascular resistance of 3.2 Wood units
and led to an increase in cardiac output and cardiac index to 7.2 L/
min and 4.3 L/min/m2, respectively.
Shewas then initiated oral diltiazem that was titrated to 300mg
over 6 months. Despite diltiazem initiation her dyspnea progressed
from functional class II to III and a repeat echocardiogram revealed
new right ventricular enlargement, moderate-severe right ven-
tricular systolic dysfunction, right ventricular index of myocardial
performance (RIMP) of 0.85, moderate tricuspid regurgitation, and
RVSP of 102 mmHg. She was then initiated on an endothelin re-
ceptor antagonist (bosentan 125 mg twice per day) and then a
phosphodiesterase-5 inhibitor (sildenaﬁl 20 mg three times daily)
shortly thereafter. Following drug initiation, a sharp reduction in
RVSP, lessening of tricuspid regurgitation, improvement in RIMP to
0.32, and reduction in her dyspnea severity to NHYA Class II was
observed (therapeutic events summarized in Fig. 2). This regimen
was continued until January 2010 wherein she was transitioned off
sildenaﬁl 20 mg three times daily to tadalaﬁl 40 mg daily due to
difﬁculty with medication compliance (forgetting to take evening
sildenaﬁl dose). Ten years following the initiation of advanced PH
therapies, echocardiographic and functional class improvement
were sustained despite continued tobacco abuse, and lack of OSA
treatment.Fig. 2. Temporal relationship of the trend of right ventricular systolic pressure (RVSP)
values derived from serial echocardiography (2004e2014) with the use of pulmonary
vasomodulatory therapies.Discussion
PLCH is a smoking-induced diffuse lung disease with an un-
predictable clinical course. In a proportion of patients, PLCH is a
relatively benign disease which may regress spontaneously or
following smoking cessation; however in other patients, PLCH is
much more aggressive life-threatening illness. PH is a serious
complication of PLCH that manifests more commonly and with
greater severity among disease-affected patients than those with
other diffuse lung diseases [6e8]. Its development portends a
relatively poor prognosis associated with substantial reduction in
patient survival [8]. Although the mechanisms involved in its
development are not entirely clear, PLCH-related PH is at least
partially caused by a primary pulmonary vasculopathy [6e8]. A
prior study described the presence of histopathological pulmonary
vascular involvement and PH severity disproportionate to the de-
gree of pulmonary function impairment [6], suggesting that PLCH-
related PH is not caused solely by hypoxemia-induced pulmonary
vascular remodeling that typiﬁes WHO group III PH disease(s). As
illustrated in the current case report, severe PLCH-related PH is not
only observed in patients with advanced long-standing disease, but
may occur in patients with early disease and/or those with rela-
tively limited lung function impairment.
The therapeutic relationship between advanced PH therapies
and PLCH-related PH remains to be sufﬁciently characterized. Le
Pavec and colleagues recently reported that the use of advanced PH
therapy was associated with improvement in pulmonary vascular
hemodynamic parameters [5]. The current case provides a striking
example of the favorable response of advanced PH therapies for
some patients with PLCH-associated PH. Moreover, as the patient
did not quit smoking, engage in OSA treatment, or demonstrate
pulmonary function or radiographic improvements, there is no
alternative explanation for her clinical response.
Our case provides further evidence that PLCH-related PHmay be
responsive to advanced PH therapies. The identiﬁcation of those
patients responsive to advanced PH therapy provides an opportu-
nity to alleviate symptoms and potentially improve survival.References
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